According to a report from Cedrus Investment, approximately 94.7% of pregnant women in China take nutritional supplements during preconception and pregnancy. In 2021, the market for prenatal health products surpassed RMB 70 billion yuan (USD $9.61 billion). About 78% of Chinese pregnant women express a desire to purchase higher quality and more suitable nutritional supplements for themselves. However, the dominant players in this sector are still foreign brands with limited product variety. The emergence of the DACHAO series of reproductive anti-aging nutritional supplements holds the potential to break this trend.
Recently, Hainan LeYun Biotech secured RMB tens of millions of yuan (USD several million dollars) in Series B financing from Switzerland’s globally recognized financial group, Cedrus Investment. This company has successfully launched a series of reproductive nutritional supplements, including DACHAO Reco18, Reju28, PCOS, and DaJing No.1. These products address a market gap in domestically developed hormone-free ovarian function regulation, testicular function regulation, polycystic ovary syndrome (PCOS) management, and relief for menopausal symptoms. (Source: news.qq)
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE